Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026
10.1177/0269881118817166 55 FarbmanA
Resume XIGDUO XR when the patient is clinically stable and has resumed oral intake [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.2)]
Primary outcome was rate of acute healthcare utilization
PlexusDx encourages open communication between weight loss and obstetric providers to ensure coordinated, safe care
This mechanism can extend nutrient transit time through the digestive system, potentially altering how collagen peptides, amino acids, and micronutrients are absorbed and utilized by your body
